About US
Contact us
-
Bausch Health quickly revives FDA quest for ‘Significant 7’ hopeful DuobriiWhen Bausch Health’s plaque psoriasis combo drug Duobrii was rejected by the FDA in June, analysts read it as a major setback for the company’s reboot plan. But after a meeting with the FDA, that hu2018/8/31
-
Eyeing $1B annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735MEmergent BioSolutions is mobilizing its M&A war chest again. Hard on the heels of its $270 million deal for vaccine expert PaxVax, the frequent government contractor is buying Adapt Pharma and i2018/8/30
-
Targeting a market Big Pharma's fleeing, Tetraphase wins FDA nod for antibiotic XeravaJust as Big Pharmas are bailing out of antibiotics research left and right, a small biotech is pressing ahead with a new drug approval. Tetraphase Pharmaceuticals snagged an FDA nod forXerava, an in2018/8/29
-
Senators question whether Giuliani's influence scored Purdue Pharma leniency from fedsAs President Donald Trump and his administration work to tackle the opioid epidemic, two Democratic senators are looking into whether his personal attorney Rudy Giuliani secured leniency for opioid2018/8/28
-
Drugmakers large and small score FDA nods in busy week of approvalsA group of drugmakers large and small scored FDA nods in a busy week for the agency. Aside from a blockbuster nod for Shire, Kala Pharmaceuticals secured a Thursday approval for Inveltys to treat ocul2018/8/27
-
Pfizer, Astellas speed up 2 Xtandi studies in market duel with Johnson & JohnsonLocked in a prostate cancer market battle with rival Johnson & Johnson, Pfizer and its partner Astellas have acceleratedtrial timelines for Xtandi in two studies in patients withhormone-sensitiv2018/8/24
-
AstraZeneca cans HQ contractor and delays glitzy £500M project—againAstraZeneca staffers eager to move into pricey,brand-new headquarters and R&D facility in Cambridge, U.K., will have to keep waiting. After numerous delays and cost overruns, the company confi2018/8/23
-
GlaxoSmithKline’s Indian consumer sale heats up with Reckitt, Kellogg joining the fray: reportMore big-name suitors are jumping into the mix for GlaxoSmithKline’s Indian consumer health unit. After earlier reports that Danone, Nestle and others were on the verge of a bidding war, Kellogg and2018/8/22
-
NICE stands firm on 'no' vote for Roche's Perjeta in postsurgery breast cancerBack in June, England’s cost watchdog refused to recommend Roche’s Perjeta for postsurgery breast cancer patients. And it’s sticking by that decision. In a new guidance document, the National Insti2018/8/21
-
Trump urges Justice Department to target opioid makers with a ‘major lawsuit’Months ago, the Department of Justicebacked the hundreds of lawsuits that accuse drugmakers and distributors of their alleged contribution to the nation’s opioid epidemic. Now, President Donald Trum2018/8/20